Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT06001788
- Locations
- 🇺🇸
The University of Kansas, Kansas City, Kansas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 102
- Registration Number
- NCT05987696
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 180
- Registration Number
- NCT05959720
- Locations
- 🇧🇷
Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05955261
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego, San Diego, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Target Recruit Count
- 260
- Registration Number
- NCT05907486
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT05886049
- Locations
- 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05863845
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 58
- Registration Number
- NCT05849662
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 38
- Registration Number
- NCT05807932
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇩🇪Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany
🇩🇪Universitätsklinikum Aachen - Med. Klinik IV, Aachen, NRW, Germany
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Target Recruit Count
- 60
- Registration Number
- NCT05805098
- Locations
- 🇨🇳
Qiu Huiying, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.